Table 1.
Characteristics and age of approval of select COVID-19 vaccines (*approved in the USA).
| Name | Company/developer | Platform | Doses and intended interval | Efficacy against symptomatic COVID-19 | Age of approval | Clinical TrialsClinicalTrials.gov (ages) | Clinical trial phase and current status |
|---|---|---|---|---|---|---|---|
| BNT162b2 | Pfizer/BioNTech | mRNA | 2 doses 3 weeks apart | 95% | >12 years* |
NCT04816643 (6 months−11 years) |
Phase 1/2 - recruiting |
| mRNA-1273 | Moderna | mRNA | 2 doses 4 weeks apart | 94% | >12 years* |
NCT04796896 (6 months−11 years) |
Phase 2/3 - recruiting |
| Ad26.COV2.S | Janssen/Johnson & Johnson | Replication-incompetent adenovirus 26 vector | 1 dose | 66% | >18 years |
NCT04535453 (12–17 years) |
Phase 2 - active, not recruiting |
| ChAdOx1 nCov-19/AZD1222 | AstraZeneca/University of Oxford/ Serum Institute of India | Replication-incompetent chimpanzee adenovirus vector | 2 doses, 8-12 weeks apart (WHO recommendation) | 70% | >18 years | – | – |
| NVX-CoV2373 | Novavax | Recombinant protein | 2 doses 3 weeks apart | 89% | >18 years |
NCT04611802 (12–17 years) |
Phase 3 - recruiting |
| Gam-COVID-Vac (Sputnik V) | Gamaleya Institute | Replication-incompetent adenovirus 26 and adenovirus 5 vectors | 2 doses 3 weeks apart | 92% | >18 years |
NCT04954092 (12–17 years) |
Phase 2/3 - recruiting |